FDA Will Wait To Act On Plan B Petition Despite Contempt Complaint
This article was originally published in The Tan Sheet
Executive Summary
FDA does not plan to look at allowing wider access to nonprescription emergency contraceptive Plan B until Teva Pharmaceuticals files an application, despite a complaint accusing the agency of ignoring a court order to reconsider age restrictions on the product.